Cargando…

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade

OBJECTIVE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but come with immune-related adverse events (irAEs) that provide a novel challenge for treating physicians. Neuromuscular irAEs, including myositis, myasthenia gravis (MG), and demyelinating polyradiculoneuropathy, lea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelke, Christopher, Pawlitzki, Marc, Kerkhoff, Ruth, Schroeter, Christina B., Aktas, Orhan, Neuen-Jacob, Eva, Polzin, Amin, Meuth, Sven G., Ruck, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical/Scientific Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602369/ https://www.ncbi.nlm.nih.gov/pubmed/37884388 http://dx.doi.org/10.1212/NXI.0000000000200177

Ejemplares similares

Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis
por: Nelke, Christopher, et al.
Publicado: (2023)

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
por: Pawlitzki, Marc, et al.
Publicado: (2022)

Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

Bilateral Vocal Fold Paralysis in Myasthenia Gravis: A Case Report and Literature Review
por: Nelke, Christopher, et al.
Publicado: (2020)

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022)

Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021)

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
por: Nelke, Christopher, et al.
Publicado: (2022)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)

The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis
por: Labeit, Bendix, et al.
Publicado: (2020)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021)

Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life–threatening continuum of neuromuscular and cardiac toxicity
por: Rota, Eugenia, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit
por: Deharo, François, et al.
Publicado: (2022)

Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis
por: Kufukihara, Kenji, et al.
Publicado: (2019)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
por: Bai, Jing, et al.
Publicado: (2022)

Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Inclusion body myositis and associated diseases: an argument for shared immune pathologies
por: Nelke, Christopher, et al.
Publicado: (2022)

Smoldering myocarditis following immune checkpoint blockade
por: Norwood, Timothy G., et al.
Publicado: (2017)

Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
por: Yin, Beibei, et al.
Publicado: (2022)

Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Tomisaki, Ikko
Publicado: (2019)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
por: Jeyakumar, Nikeshan, et al.
Publicado: (2020)

Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells
por: Schroeter, Christina B., et al.
Publicado: (2021)

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases
por: Oeztuerk, Menekse, et al.
Publicado: (2023)

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany
por: Masanneck, Lars, et al.
Publicado: (2023)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Anti-Kv1.4 Antibody Without Myasthenia Gravis: A Rare Cause of Autoimmune Myocarditis and Myositis
por: Kuyama, Naoto, et al.
Publicado: (2023)

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
por: Xing, Qian, et al.
Publicado: (2020)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation
por: Menghesha, Hruy, et al.
Publicado: (2023)

Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report
por: Zhou, Zhijian, et al.
Publicado: (2019)

High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies
por: Nelke, Christopher, et al.
Publicado: (2022)

Skeletal muscle as potential central link between sarcopenia and immune senescence
por: Nelke, Christopher, et al.
Publicado: (2019)

Giant cell myositis and myocarditis revisited
por: Oflazer, Piraye
Publicado: (2020)

Statin-Induced Myositis with Concomitant Myocarditis
por: Patail, Haris, et al.
Publicado: (2022)

Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor‐related myocarditis and myositis: rechallenge?
por: Rossi, Valentina A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ulrf07fhdn6e5ob18qnc6n2tid